

# Alexei A Grom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9662715/publications.pdf>

Version: 2024-02-01

65  
papers

6,476  
citations

87723

38  
h-index

114278

63  
g-index

65  
all docs

65  
docs citations

65  
times ranked

5977  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritisâ€“Associated Interstitial Lung Disease. <i>Arthritis Care and Research</i> , 2023, 75, 983-988.	1.5	7
2	Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Stillâ€™s Disease in the U.S. Real-World Settings. <i>Rheumatology and Therapy</i> , 2022, 9, 265-283.	1.1	1
3	Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-Î³ hyper-responsiveness and risk for macrophage activation syndrome. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 617-625.	0.5	31
4	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 406-408.	0.5	53
5	Repression of CTSC, ELANE and PRN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. <i>Nature Immunology</i> , 2021, 22, 711-722.	7.0	36
6	Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e574-e584.	2.2	77
7	Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States. <i>Pediatric Rheumatology</i> , 2021, 19, 143.	0.9	1
8	IFN-Î³ is essential for alveolar macrophageâ€“driven pulmonary inflammation in macrophage activation syndrome. <i>JCI Insight</i> , 2021, 6, .	2.3	18
9	Targeting interferon-Î³ in hyperinflammation: opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2021, 17, 678-691.	3.5	57
10	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNÎ³) Monoclonal Antibody. <i>Blood</i> , 2021, 138, 2058-2058.	0.6	5
11	Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNÎ³) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases. <i>Blood</i> , 2021, 138, 4195-4195.	0.6	3
12	IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. <i>Rheumatology</i> , 2020, 59, 442-445.	0.9	50
13	IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. <i>Rheumatology</i> , 2020, 59, 361-366.	0.9	73
14	A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1204-1208.e6.	1.5	45
15	The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. <i>Pediatric Rheumatology</i> , 2020, 18, 7.	0.9	24
16	On the Alert for Cytokine Storm: Immunopathology in COVID-19. <i>Arthritis and Rheumatology</i> , 2020, 72, 1059-1063.	2.9	562
17	Systemic Juvenile Idiopathic Arthritisâ€“Associated Lung Disease: Characterization and Risk Factors. <i>Arthritis and Rheumatology</i> , 2019, 71, 1943-1954.	2.9	124
18	Emergent high fatality lung disease in systemic juvenile arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1722-1731.	0.5	122

#	ARTICLE	IF	CITATIONS
19	A Multiparameter Flow Cytometry Analysis Panel to Assess CD163 mRNA and Protein in Monocyte and Macrophage Populations in Hyperinflammatory Diseases. <i>Journal of Immunology</i> , 2019, 202, 1635-1643.	0.4	19
20	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2019, 71, 451-459.	2.9	36
21	Genetics of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. , 2019, , 131-138.		1
22	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1508-1518.	2.9	26
23	MicroRNA networks associated with active systemic juvenile idiopathic arthritis regulate CD163 expression and anti-inflammatory functions in macrophages through two distinct mechanisms. <i>Journal of Leukocyte Biology</i> , 2018, 103, 71-85.	1.5	19
24	Brief Report: Novel <i>UNC13D</i> Intronic Variant Disrupting an NF- $\kappa$ B Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 963-970.	2.9	30
25	Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. <i>Blood</i> , 2018, 131, 1442-1455.	0.6	288
26	Neutralization of IFN- $\gamma$ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1439-1449.	1.5	96
27	Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2995.	2.2	54
28	Identification of enhanced IFN- $\gamma$ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. <i>JCI Insight</i> , 2018, 3, .	2.3	22
29	Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis. <i>Blood</i> , 2018, 132, LBA-6-LBA-6.	0.6	15
30	Elevated circulating levels of interferon- $\gamma$ and interferon- $\gamma$ -induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 166-172.	0.5	222
31	Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. <i>Rheumatology</i> , 2017, 56, 1542-1551.	0.9	12
32	Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by $\gamma\delta$ T Cells in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1480-1494.	2.9	71
33	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 906-913.	0.5	123
34	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 13.	1.6	49
35	Urine S100 proteins as potential biomarkers of lupus nephritis activity. <i>Arthritis Research and Therapy</i> , 2017, 19, 242.	1.6	50
36	Monocyte MicroRNA Expression in Active Systemic Juvenile Idiopathic Arthritis Implicates MicroRNA-125a-5p in Polarized Monocyte Phenotypes. <i>Arthritis and Rheumatology</i> , 2016, 68, 2300-2313.	2.9	62

#	ARTICLE	IF	CITATIONS
37	A Heterozygous <i>RAB27A</i> Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. <i>Journal of Immunology</i> , 2016, 196, 2492-2503.	0.4	77
38	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	2.9	427
39	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. <i>Arthritis and Rheumatology</i> , 2016, 68, 218-228.	2.9	103
40	Relationship of cell-free urine MicroRNA with lupus nephritis in children. <i>Pediatric Rheumatology</i> , 2016, 14, 4.	0.9	16
41	Macrophage activation syndrome in the era of biologic therapy. <i>Nature Reviews Rheumatology</i> , 2016, 12, 259-268.	3.5	323
42	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.5	338
43	Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza. <i>Journal of Infectious Diseases</i> , 2016, 213, 1180-1188.	1.9	133
44	Systemic onset juvenile idiopathic arthritis and exposure to fine particulate air pollution. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 946-952.	0.4	8
45	Reply. <i>Arthritis Care and Research</i> , 2015, 67, 1615-1616.	1.5	0
46	11-Month-Old Infant With Periodic Fevers, Recurrent Liver Dysfunction, and Perforin Gene Polymorphism. <i>Arthritis Care and Research</i> , 2015, 67, 1173-1179.	1.5	19
47	A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFN $\gamma$ ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH. <i>Blood</i> , 2015, 126, LBA-3-LBA-3.	0.6	48
48	Whole-Exome Sequencing Reveals Overlap Between Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Familial Hemophagocytic Lymphohistiocytosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3486-3495.	2.9	158
49	Canakinumab for the treatment of systemic juvenile idiopathic arthritis. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1427-1435.	1.3	6
50	Macrophage activation syndrome and cytokine-directed therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 277-292.	1.4	127
51	Genetic Defects in Cytolysis in Macrophage Activation Syndrome. <i>Current Rheumatology Reports</i> , 2014, 16, 439.	2.1	113
52	The limited role of interferon $\gamma$ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness. <i>Arthritis and Rheumatism</i> , 2012, 64, 3799-3808.	6.7	43
53	Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. <i>Nature Reviews Rheumatology</i> , 2011, 7, 416-426.	3.5	263
54	Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2011, 117, e151-e160.	0.6	85

#	ARTICLE	IF	CITATIONS
55	Macrophage activation syndrome: advances towards understanding pathogenesis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 561-566.	2.0	178
56	Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13 $\epsilon$ polymorphisms. <i>Arthritis and Rheumatism</i> , 2008, 58, 2892-2896.	6.7	155
57	The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor $\beta$ -chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 965-971.	6.7	294
58	Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 3793-3804.	6.7	216
59	Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?. <i>Arthritis and Rheumatism</i> , 2004, 50, 689-698.	6.7	204
60	Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. <i>Journal of Pediatrics</i> , 2003, 142, 292-296.	0.9	257
61	Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?. <i>Current Opinion in Rheumatology</i> , 2003, 15, 587-590.	2.0	130
62	Expression of angiogenic factors in juvenile rheumatoid arthritis: Correlation with revascularization of human synovium engrafted into SCID mice. <i>Arthritis and Rheumatism</i> , 2001, 44, 794-801.	6.7	38
63	Comparative sequence analysis of the human T cell receptor $\beta$ chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: Evidence for antigenic selection of T cells in the synovium. <i>Arthritis and Rheumatism</i> , 1998, 41, 482-497.	6.7	37
64	Patterns of expression of tumor necrosis factor $\alpha$ , tumor necrosis factor $\beta$ , and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. <i>Arthritis and Rheumatism</i> , 1996, 39, 1703-1710.	6.7	167
65	Juvenile rheumatoid arthritis and the trimolecular complex (hla, t cell receptor, and antigen). <i>Arthritis and Rheumatism</i> , 1994, 37, 601-607.	6.7	29